Abstract: Disclosed are methods of manufacturing a flash memory device. The method can include performing a first test on memory banks of chips on a wafer to record an availability of the banks; performing an inking process on each of the chips according to a number of available banks in the chip; performing a sawing process to divide the chips mounted on the wafer; packaging the divided chips according to the number of available banks in the chip; and performing a verification test on the packaged chips.
Abstract: A magnetic memory device and a manufacturing method thereof are provided. The magnetic memory device can include a word line, a freely switchable layer, a fixed layer, a dielectric layer, and a bit line. The freely switchable layer can be electrically connected to a diffusion region at one side of the word line, and the fixed layer can be horizontally adjacent to the freely switchable layer. The dielectric layer can be provided between the freely switchable layer and the fixed layer, and the bit line can be electrically connected to the fixed layer.
Abstract: An image sensor and a method of manufacturing the same are provided. A metal wiring layer is formed on a semiconductor substrate including a circuit region, and first conductive layers are formed on the metal layer separated by a pixel isolation layer. An intrinsic layer is formed on the first conductive layers, and a second conductive layer is formed on the intrinsic layer.
Abstract: The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.
Type:
Grant
Filed:
August 2, 2005
Date of Patent:
June 8, 2010
Assignees:
Innate Pharma S.A., University of Genova
Inventors:
Alessandro Moretta, Roberta Castriconi, Christina Bottino, Lorenzo Moretta
Abstract: A pump system having a pump module (10) comprising a stator housing (28) with a chamber (30), a rotor (32) rotatably and axially slidably received in the chamber and comprising a first axial extension (46) with a liquid supply channel (50) and a second axial extension with a liquid supply channel (52), the first and second axial extensions having different diameters, and first and second sealing rings (54, 56), mounted around the first and second axial extensions.
Type:
Grant
Filed:
October 15, 2004
Date of Patent:
June 1, 2010
Assignee:
Sensile Pat AG
Inventors:
Peter Ryser, Sigfrid Straessler, Josef Hilber
Abstract: Optical parametric oscillator including a semiconductor microcavity being configured to spatially localize polaritons of at least three quantized polariton energy levels to effect an optical parametric oscillation.
Type:
Grant
Filed:
January 30, 2007
Date of Patent:
June 1, 2010
Assignee:
École Polytechnique Fédérale de Lausanne
Inventors:
Ounsi El Daif, Augustin Baas, Benoît Deveaud-Plédran, François Morier-Genoud
Abstract: Compounds that may have anti-inflammatory activity are of general formula (I); wherein X1, is H or COR1, and X2 is H or COR2 but X1, and X2 are not both H; R1 and R2 are the same or different and are each C1-4 alkyl substituted with R3, or a four to seven-membered ring which can be optionally substituted with R8 and can contain one or more additional heteroatoms selected from O, S(O)n and NR9; is R3 is F, CF3, OR4, NR5R6 O, S(O)n R7; R4, R5 and R6 are the same or different and are each H or C1-4 alkyl optionally substituted with R3, or NR5R6 is a C4-6 heterocycloalkyl ring containing one or more heteroatoms selected from O, NR8 and S(O)n; each n is 0-2; R7 is C1-4 alkyl; R8 is as defined for R3 or C1-4 alkyl optionally substituted with R3 or halogen; and R9 is H or C1-4 alkyl; or a salt, solvate or hydrate thereof.
Abstract: A compound of the formula (I) wherein each Z is the same or different and is formula (a) or —Y wherein each X is the same or different and is a multivalent aminyl group or diaminyl-terminated spacer; each Y is the same or different aminyl group; and M is a support matrix.
Type:
Grant
Filed:
December 9, 2003
Date of Patent:
May 25, 2010
Assignee:
Prometic Biosciences Ltd.
Inventors:
Steven James Burton, Abid Hussain, James Christopher Pearson
Abstract: The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising a mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid.
Abstract: The subject invention provides a shield for protecting a patient's extremities when positioned on an arm or leg board or other surgical or examination table extension. The shield comprises essentially an inverted C-shaped or U-shaped covering with a channel therein. It may further comprise one or more flanges to aid in supporting and positioning the shield.
Type:
Grant
Filed:
December 13, 2006
Date of Patent:
May 18, 2010
Assignee:
University of Florida Research Foundation, Inc.
Abstract: The present invention is based in part on the discovery that the upstream open reading frame (uORF) in the extended 5?-untranslated region (5?-UTR) argininosuccinate synthase (AS) mRNA species is functional, and when functional, limits overall AS expression as well as nitric oxide (NO) production. Thus, the extended 5?-UTR AS mRNA species is a mechanism for regulating AS expression and NO production, and provides a target for the treatment of pathophysiological conditions associated with vascular endothelial dysfunction and characterized by impairment of NO production, such as heart failure, hypertension, hypercholesterolemia, atherosclerosis, and diabetes.
Type:
Grant
Filed:
January 27, 2006
Date of Patent:
May 18, 2010
Assignee:
University of South Florida
Inventors:
Duane C. Eichler, Larry P. Solomonson, Laura C. Pendleton
Abstract: Provided is a camera module. The camera module includes an aperture stop, a first lens, a second lens, a third lens, and an image sensor. The first lens has a positive refractive power to transmit light that has passes through the aperture stop, and the second lens has a negative refractive power to transmit light that has passed through the first lens. The third lens has a negative refractive power to transmit light that has passed through the second lens. The image sensor detects light that has passed through the third lens.
Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
Abstract: Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP?/? which exhibits enhanced survival following mismatched allogeneic marrow grafts.
Abstract: The subject invention provides a process and apparatus for making “enhanced water” that is uniquely suitable for improving circulation, hydration and insulin usage with diabetics. Thus, in a preferred embodiment, the invention provides methods for the treatment and/or prevention of diabetes as well as the prevention or delay in development of diabetes-related complications, conditions or diseases.
Abstract: The present invention discloses novel pest control compounds comprising NPF polypeptides and methods for using such compounds in the control of pests.
Type:
Grant
Filed:
February 6, 2009
Date of Patent:
May 11, 2010
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Dov Borovsky, Arnold De Loof, Peter Verhaert
Abstract: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.
Type:
Grant
Filed:
December 20, 2005
Date of Patent:
May 11, 2010
Assignee:
Merck Serono S.A.
Inventors:
Giampiero De Luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
Abstract: A method for manufacturing an image sensor according to an embodiment includes performing a plasma surface treatment on an oxide film microlens to mitigate high surface morphology. The image sensor can include a passivation layer on a substrate having a pad region and a pixel region and a color filter layer on the passivation layer. A first low temperature oxide can be formed over the substrate including the color filter layer; and an oxide film microlens can be formed on the first low temperature oxide layer. A portion of the first low temperature oxide layer can provide a seed microlens upon which a second low temperature oxide layer is formed to form the oxide film microlenses. The plasma surface treatment can then be applied with respect to the oxide film microlenses.
Abstract: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.
Type:
Grant
Filed:
July 19, 2006
Date of Patent:
May 4, 2010
Assignee:
CYTHERIS
Inventors:
Michel Morre, Brigitte Assouline, Iann Rance, Anne Gregoire, Corinne Breque
Abstract: A method for manufacturing a semiconductor device is provided. In particular, a method for removing unwanted material layers from an edge and lower bevel region of a wafer is provided. The method includes performing a first etch of an edge region of a wafer having material layers formed thereon, coating the wafer with a photoresist layer, and patterning the photoresist layer to expose at least the edge and an upper bevel region of the wafer for etching the material layers remaining after performing the first etch.